Astellas’ Vaprisol Receives Second Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
Vasopressin antagonist clears FDA for treatment of hospitalized patients with hypervolemic hyponatremia.
You may also be interested in...
Cornerstone’s Hyponatremia Therapy Lixivaptan Will Get Advisory Panel Scrutiny
The hyponatremia drug is a selective vasopressin V2-receptor antagonist, like Astellas’ Vaprisol and Otsuka’s Samsca.
Biogen Idec Partners With Cardiokine On Vasopressin Antagonist For Hyponatremia
Phase III trials of the oral drug, which will start this year, are expected to take two years to complete, Biogen says.
Biogen Idec Partners With Cardiokine On Vasopressin Antagonist For Hyponatremia
Phase III trials of the oral drug, which will start this year, are expected to take two years to complete, Biogen says.